Małgorzata M. Monika Michalska-Jakubus

Prof. Dr. Małgorzata M. Monika Michalska-Jakubus


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2010 in Rheumatology
Verified
Journal Article
Open access
PDF file
MMMałgorzata M. Monika Michalska-Jakubus
Małgorzata M. Monika Michalska-Jakubus
OKOtylia Kowal-Bielecka
Otylia Kowal-Bielecka
GCGrażyna Chodorowska
Grażyna Chodorowska
MBMarek Bielecki
Marek Bielecki
Dorota KrasowskaDorota Krasowska
Dorota Krasowska
Objectives. The aim of the study was to investigate serum concentration of angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) in SSc patients and to correlate Ang-1 and -2 levels with clinical manifestations. Methods. Serum levels of Ang-1 and -2 were determined by ELISA in 47 SSc patients and 27 healthy controls matched for age and sex. Results. In SSc patients, Ang-1 was significantly lower [mean (s.d.): 21 666.09 (11 516.06) pg/ml], while Ang-2 was significantly increased [2739.60 (1009.25) pg/ml] when compared with the control group [Ang-1: 28607.13 (10 506.93) pg/ml; Ang-2: 1706.28 (556.28) pg/ml, P < 0.01, for both comparisons]. No correlation was observed between Ang-1 and -2 levels. Serum concentrations of Ang-2 correlated with the modified Rodnan skin score (P < 0.01, r = 0.422), the European Scleroderma Study Group (EScSG) disease activity index score (P < 0.001, r = 0.403), ESR (P < 0.05, r = 0.366) and CRP concentration (P < 0.05, r = 0.292), and showed inverse correlation with diffusing capacity for carbon monoxide (DLCO) (P < 0.01, r = −0.281). Ang-2 was significantly increased in SSc patients with more advanced capillary damage, as indicated by the presence of late capillaroscopic pattern, than in those with less severe microangiopathy (active pattern), and in SSc patients with intermediate/late stage of disease than in SSc subjects with early disease. In multivariate regression analysis, Ang-2 was independently associated with the EScSG activity index [β-coefficient (β = 0.305, P = 0.038], ESR (β = 0.390, P = 0.006) and, inversely, with the presence of digital ulcers (β = −0.426, P = 0.003). Conclusions. Differential expression of Ang-1/Ang-2 might contribute to the pathogenesis of SSc. Ang-2 might be a new biomarker of disease activity in SSc.

1 September 2019 in Microvascular Research
Verified
Journal Article
Closed access
MMMałgorzata M. Monika Michalska-Jakubus
Małgorzata M. Monika Michalska-Jakubus
MCMaurizio Cutolo
Maurizio Cutolo
VSVanessa Smith
Vanessa Smith
Dorota KrasowskaDorota Krasowska
Dorota Krasowska

24 June 2013 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
OKOtylia Kowal-Bielecka
Otylia Kowal-Bielecka
MBMarek Bielecki
Marek Bielecki
SGSerena GUIDUCCI
Serena GUIDUCCI
BTBeata Trzcinska-Butkiewicz
Beata Trzcinska-Butkiewicz
MMMałgorzata M. Monika Michalska-Jakubus
Małgorzata M. Monika Michalska-Jakubus
KKKrzysztof Kowal
Krzysztof Kowal
Introduction: Systemic sclerosis (SSc) is an autoimmune disease characterized by chronic inflammation, vascular injury and excessive fibrosis. CD163 is a scavenger receptor which affects inflammatory response and may contribute to connective tissue remodelling. It has recently been demonstrated that CD163 can bind and neutralize the TNF-like weak inducer of apoptosis (TWEAK), a multifunctional cytokine which regulates inflammation, angiogenesis and tissue remodelling. We aimed to investigate the relationships between serum levels of soluble CD163 (sCD163) and soluble TWEAK (sTWEAK) in relation to disease manifestations in SSc patients. Methods: This study included 89 patients with SSc who had not received immunosuppressive drugs or steroids for at least 6 months and 48 age- and sex-matched healthy controls (HC) from four European centres. Serum concentrations of sTWEAK and sCD163 were measured using commercially available ELISA kits. Results: The mean serum concentrations of sTWEAK were comparable between SSc patients (mean +/- SD: 270 +/- 171 pg/mL) and HC (294 +/- 147pg/mL, P >0.05). Concentration of sCD163 and sCD163/sTWEAK ratio were significantly greater in SSc patients (984 +/- 420 ng/mL and 4837 +/- 3103, respectively) as compared to HC (823 +/- 331 ng/mL and 3115 +/- 1346 respectively, P mean +2SD of HC) were both associated with a lower risk of digital ulcers in SSc patients (OR, 95%CI: 0.09; 0.01, 0.71, and 0.17; 0.06, 0.51, respectively). Accordingly, patients without digital ulcers had a significantly higher sCD163 concentration and sCD163/sTWEAK ratio as compared to SSc patients with digital ulcers (P <0.01 for both) and HC (P <0.05 for both). A high sCD163/sTWEAK ratio, but not high sCD163 levels, was associated with greater skin involvement. Conclusions: The results of our study indicate that CD163-TWEAK interactions might play a role in the pathogenesis of SSc and that CD163 may protect against the development of digital ulcers in SSc. Further studies are required to reveal whether targeting of the CD163-TWEAK pathway might be a potential strategy for treating vascular disease and/or skin fibrosis in SSc.


Verified
Journal Article
Open access
PDF file
PSPaulina Szczepanik-Kułak
Paulina Szczepanik-Kułak
MMMałgorzata M. Monika Michalska-Jakubus
Małgorzata M. Monika Michalska-Jakubus
Dorota KrasowskaDorota Krasowska
Dorota Krasowska
Morphea, also known as localized scleroderma (LoS), comprises a set of autoimmune sclerotic skin diseases. It is characterized by inflammation and limited thickening and induration of the skin; however, in some cases, deeper tissues might also be involved. Although morphea is not considered a life-threatening disease, the apparent cosmetic disfigurement, functional or psychosocial impairment affects multiple fields of patients’ quality of life. Therapy for LoS is often unsatisfactory with numerous treatments that have only limited effectiveness or considerable side effects. Due to the advances in the application of lasers and their possible beneficial effects, the aim of this study is to review the reported usage of laser in morphea. We present a systematic review of available literature, performed with MEDLINE, Cinahl, Central, Scopus, Web of Science, and Google Scholar databases. We identified a total of twenty relevant studies (MEDLINE n = 10, Cinahl n = 1, Central n = 0, Scopus n = 2, Web of Science n = 5, Google Scholar n = 2) using laser therapy for LoS. Eight studies were focused on the use of PDL, six on fractional lasers (CO2 and Er:YAG), four on excimer, and two on either alexandrite or Nd:YAG.

1 January 2020 in Advances in Dermatology and Allergology
Verified
Journal Article
Open access
PDF file
MMMałgorzata M. Monika Michalska-Jakubus
Małgorzata M. Monika Michalska-Jakubus
MRMarta Rusek
Marta Rusek
MKMałgorzata Kowal
Małgorzata Kowal
Marcin CzopMarcin Czop
Marcin Czop
JKJanusz Kocki
Janusz Kocki
Dorota KrasowskaDorota Krasowska
Dorota Krasowska
Introduction Evidence has accumulated for the role of endothelial damage in systemic sclerosis (SSc) and the anti-endothelial cell antibodies (AECAs) might underlie vascular injury. Aim Since endothelial microparticles (EMPs) and circulating endothelial cells (CECs) reflect endothelial...